Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Health Sciences Authority
New Drug Indication Approvals

New drug indication approval - February 2024

Audiences

Healthcare professional

Industry member

Product type

Therapeutic Products

7 May 2024

This article has been migrated from an earlier version of the site and may display formatting inconsistencies.

Table caption

Product Name

RINVOQ EXTENDED-RELEASE TABLET 15MG,
RINVOQ EXTENDED-RELEASE TABLETS 30 MG,
RINVOQ EXTENDED-RELEASE TABLET 45MG

Active Ingredient (Strength)

Upadacitinib Hemihydrate eqv Upadacitinib(15mg),
Upadacitinib Hemihydrate eqv Upadacitinib(30mg),
Upadacitinib Hemihydrate eqv Upadacitinib(45mg)

Product Registrant

ABBVIE PTE. LTD.

Date of Approval

16/02/2024

Indications:
Crohn’s Disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Back to top